Reaching a weight goal creates a different treatment question from starting a GLP-1: can a lower dose preserve the result? SURMOUNT-MAINTAIN tested that question directly. After 60 weeks of tirzepatide treatment, participants continued their maximum tolerated dose, moved down to 5 mg weekly, or switched to placebo for another year. The lower dose did better than stopping, while continuing the higher dose preserved more of the overall weight reduction.[1]
The useful distinction is between reducing treatment and ending it. Neither choice can be evaluated from a starter-month price or a before-and-after photograph. The separate withdrawal-trial overview explains what happened when treatment stopped completely; this trial adds a randomized middle option. It does not establish that everyone who reaches a goal should lower their dose, or that a particular calendar date is the right moment to try.
The trial began a year before the maintenance comparison
SURMOUNT-MAINTAIN enrolled adults with obesity, or overweight accompanied by a weight-related condition, at 20 US sites. Everyone initially received open-label tirzepatide, escalating to a maximum tolerated weekly dose of 10 or 15 mg. That first phase lasted 60 weeks. Of 441 people who received treatment during it, 378 entered the randomized maintenance phase: 140 continued the higher dose, 144 received 5 mg, and 94 received placebo.[1]
That structure defines the population the results describe. These were people who had already spent more than a year on the drug and reached the maintenance comparison. Someone deciding whether to begin tirzepatide has a different question, as does someone who cannot tolerate the early escalation. A successful run-in creates a selected group; it cannot establish the same outcome for every new prescription.
It also separates this study from informal dose experimentation. The randomized comparison used a specified weekly dose, blinded treatment, scheduled follow-up, and an agreed rescue rule. Skipping injections, dividing vial contents without a prescribed plan, and changing concentrations are different interventions. The discussion of GLP-1 tapering covers why an attractive pharmacologic explanation is not equivalent to a tested regimen.
Read the percentages from the original starting weight
At week 112, estimated weight change from the original baseline was −21.9% with continued maximum-dose treatment, −16.6% after reduction to 5 mg, and −9.9% with placebo. The 95% confidence intervals (95% CI) were −23.5% to −20.3%, −18.0% to −15.1%, and −11.1% to −8.8%, respectively. The two active strategies each outperformed placebo on the reported primary comparison.[1]
Those figures are total changes over the whole study, including the shared weight-loss phase. They do not mean the 5 mg group lost an additional 16.6% after lowering the dose. Nor does the placebo result mean stopping tirzepatide produced a fresh 9.9% reduction. Confusing the starting point reverses the practical meaning of a maintenance study.
For illustration, a 16.6% reduction from an original 250 pounds is 41.5 pounds below that original weight. That arithmetic only translates the percentage; it predicts neither a particular person's final weight nor how much they would regain after reducing a dose. The relevant comparison is the average result under three assigned strategies. A clinician still needs the person's actual trajectory, tolerability, health goals, and preferences.
A lower dose helped, but it was not equivalent
The numerical gap between the maximum-dose and 5 mg groups was 5.3 percentage points of original body weight. That is a reason to avoid describing the study as proof that the lower dose works just as well. Its more defensible message is narrower: continuing some treatment can offer a meaningful alternative to withdrawing it, while a higher tolerated dose may preserve more benefit.
There are several reasons someone might raise this option with a prescriber: treatment burden, persistent side effects, preference, or affordability. The trial can inform that conversation without deciding it. A maintenance dose is a prescription decision attached to a particular person, rather than a reward for reaching an arbitrary target. The weight-loss plateau article explains why a flattening scale alone does not show that treatment has stopped helping.
Zepbound prescribing information lists 5, 10, and 15 mg weekly as maintenance doses for weight reduction and long-term maintenance, with selection based on response and tolerability. Its 2.5 mg starting dose is an initiation step, not a listed maintenance dose for that indication.[2] SURMOUNT-MAINTAIN adds evidence about stepping down after established higher-dose treatment; it does not turn every smaller dose into a validated maintenance strategy.
The rescue rule matters
From week 84, participants who regained more than half their previous weight loss could receive rescue tirzepatide. Reported rescue use was 11 of 138 participants on the maximum-dose strategy, 35 of 142 on 5 mg, and 60 of 90 on placebo: approximately 8%, 25%, and 67%. The primary analysis used a modified treatment-regimen approach that made a specified assumption about outcomes after rescue.[1]
For a reader, the implication is that these numbers do not describe three groups simply left untouched for a year regardless of what happened. Rescue was part of the study design. A trial estimate and an observed final weight can therefore answer subtly different questions. The final percentages should travel with the study's treatment strategy and analysis description, rather than being presented as an inevitable natural course.
Rescue also explains why a maintenance discussion needs follow-up. A dose change without an agreed review point leaves no shared definition of success or deterioration. Useful questions include what changes should trigger a call, how adverse effects will be assessed, and how the prescribing team will review weight-related health outcomes. This is different from supplying an unsupervised threshold or a self-directed restart schedule.
Earlier withdrawal studies answer a neighboring question
SURMOUNT-4 tested continuation against withdrawal after a shorter tirzepatide lead-in. During its randomized phase, participants who switched to placebo regained weight, whereas those who continued treatment lost more. That establishes the importance of continuing treatment in its studied population; it does not by itself identify the smallest effective maintenance dose.[3]
The STEP 1 extension followed people after semaglutide and the study lifestyle intervention ended. Participants regained roughly two-thirds of the weight previously lost over the following year, with several cardiometabolic measures moving back toward baseline.[4] It is supporting context for obesity as a condition that often needs sustained management, not a direct comparison of semaglutide against tirzepatide dose reduction. Different drugs, designs, and starting points cannot be joined into one personal prediction.
Less medication does not automatically mean a lower bill
A dose reduction and a price reduction are separate facts. Some providers charge the same amount across doses; others price by dose, vial, or treatment period. Coverage and refill rules can matter as much as the milligrams. The maintenance-cost guide addresses those plan structures, and the GLP-1 cost calculator can help compare stated ongoing charges.
A useful quote identifies the prescribed product, supply duration, required upfront payment, consultation charges, and what happens at renewal. Dividing a large upfront package by several months produces a comparison figure, not proof that the seller offers monthly cancellation. This distinction matters particularly when a person is considering a regimen change and may need a different supply at the next review.
The trial studied tirzepatide treatment under controlled conditions, not whichever compounded product an online seller offers. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, efficacy, or quality before dispensing. The study cannot verify a seller's formulation, concentration, dispensing accuracy, or advertised equivalence. A similar ingredient name does not make the product or the evidence interchangeable.
What to bring to the prescribing conversation
Bring the current dose and product, the weight trend rather than one reading, ongoing adverse effects, other prescriptions, and the actual renewal terms. Ask which health outcomes the treatment is intended to maintain and how a change would be reviewed. The evidence supports considering lower-dose continuation for some established patients; it does not supply a universal taper, prove permanent maintenance, or show that follow-up is unnecessary.
It helps to distinguish the reason for a change from the way success will be judged. Reducing treatment because of side effects poses a different tradeoff from reducing it because coverage changed. A plan can record both the desired improvement and the possibility of losing some benefit, so a later appointment can evaluate what actually happened instead of relying on an impression from a single week.
The most useful result is the existence of a studied middle option. Continuing the maximum tolerated dose maintained more of the average reduction; 5 mg retained less, but substantially more than withdrawal. A decision can acknowledge both findings. Treating every plateau as failure or every lower-dose success as proof that medication can end would discard the very comparison the trial was designed to make.